INSP:NYE-Inspire Medical Systems Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 182.18

Change

-8.57 (-4.49)%

Market Cap

USD 6.34B

Volume

0.74M

Analyst Target

USD 81.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.70 (-0.60%)

USD 201.96B
MDT Medtronic PLC

-0.33 (-0.37%)

USD 115.52B
STE STERIS plc

-0.46 (-0.21%)

USD 21.88B
ZBH Zimmer Biomet Holdings Inc

+0.03 (+0.03%)

USD 21.28B
GMED Globus Medical

-0.88 (-1.05%)

USD 11.01B
SNN Smith & Nephew SNATS Inc

+0.04 (+0.16%)

USD 10.91B
BIO Bio-Rad Laboratories Inc

-1.33 (-0.36%)

USD 10.06B
PEN Penumbra Inc

-0.17 (-0.07%)

USD 9.07B
GKOS Glaukos Corp

-0.38 (-0.26%)

USD 7.82B
ITGR Integer Holdings Corp

+0.67 (+0.49%)

USD 4.59B

ETFs Containing INSP

QSML WisdomTree U.S. SmallCap .. 0.85 % 0.00 %

-0.25 (-0.86%)

USD 6.76M
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.51 (-0.86%)

USD 0.18B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.45% 37% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.45% 37% F 14% F
Trailing 12 Months  
Capital Gain 24.99% 63% D 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.99% 63% D 62% D
Trailing 5 Years  
Capital Gain 184.70% 96% N/A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 184.70% 96% N/A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 36.63% 87% B+ 90% A-
Dividend Return 36.63% 87% B+ 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.90% 20% F 12% F
Risk Adjusted Return 48.91% 83% B 66% D+
Market Capitalization 6.34B 65% D 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.